Finnish Media Report on Approval of REMICADE for Pediatric Crohn's DiseaseSeptember 12, 2007
The EU approval of REMICADE for treatment of pediatric Crohn's disease was reported by Crohn & Colitis, a Finnish magazine published by a patient advocacy group of the same name. It reports that the new indication for REMICADE allows for the treatment of severe, active Crohn?s disease in pediatric patients ages 6 to 17 who have not responded to conventional therapy or who are intolerant to, or have contraindications for, such therapies.
UC since 1986.
Asacol - four a day
6 MP - one a day.
Remicade - every eight weeks.